[Featured Stock] Humasis Soars Over 19% on US Approval of COVID-19 Antigen Test Kit
[Asia Economy Reporter Park Jihwan] Humasis is experiencing a surge of over 19% following the news of the Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for the COVID-19 rapid diagnostic kit jointly developed with Celltrion.
According to the Korea Exchange on the 19th, as of 10:50 AM, Humasis was trading at 14,350 KRW, up 2,300 KRW (19.09%) from the previous trading day. Earlier in the session, the stock price rose as much as 27.39%, approaching the upper price limit.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- One in 77 Koreans Exposed to Drugs... Enough Money for 6,600 Luxury Gangnam Apartments Circulates in Drug Market [ChwiYakGukga] ⑩
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
On the same day, Humasis announced that the COVID-19 rapid antigen diagnostic kit "Diatrust," co-developed with Celltrion, had received Emergency Use Authorization from the U.S. FDA.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
